Seth Harmon
Fortune : 138 317 $ au 31/05/2026
Fortune : 138 317 $ au 31/05/2026
Seth Harmon is currently Chief Financial & Accounting Officer at Viridian Therapeutics, Inc. since 2023.
Formerly, Mr. Harmon was Chief Financial Officer at BioNTech SE from 2020 to 2023 and Vice President-Finance at BioNTech US, Inc. from 2017 to 2020.
Mr. Harmon completed undergraduate studies at Bowdoin College and earned graduate degrees, including an MBA, from Northeastern University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 7 850 ( 0,01% ) | 138 317 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Directeur Financier/CFO | 12/09/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
| BIONTECH SE | Directeur Financier/CFO | 01/05/2023 |
| NEON THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2020 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Bowdoin College
Bowdoin College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNTech SE
BioNTech SE BiotechnologyHealth Technology Develops immunotherapies and mRNA-based vaccines to treat cancer & infectious diseases | Health Technology |
BioNTech US, Inc.
BioNTech US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immunotherapies for cancer | Health Technology |
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures monoclonal antibody products | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national